GlassScriptPhysician profile
Richard S Zelkowitz
NPI 1891780805
$53,824.23
in general payments reported to CMS, 2019-2025
23 companies · $8,946 in 2025
The $8,946 reported for 2025 was more than what 88% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $6,666 · 2021: $1,589 · 2022: $11K · 2023: $8,454 · 2024: $4,629 · 2025: $8,946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Food and Beverage: $1,607 · Education: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,285.00 |
| Food and Beverage | $1,607.21 |
| Education | $136.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $16,807.22 | 2019-2025 | Lynparza, Enhertu, Imfinzi |
| Pfizer INC. | $8,640.00 | 2019-2025 | |
| Lilly USA, LLC | $4,656.37 | 2019-2023 | |
| Abbvie INC. | $4,029.77 | 2019-2024 | |
| Amgen INC. | $3,784.38 | 2019 | |
| Puma Biotechnology, INC. | $3,392.00 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $3,219.04 | 2019-2025 | |
| Seagen INC. | $2,990.69 | 2021-2023 | Tukysa |
| Gilead Sciences, INC. | $2,603.82 | 2021-2025 | Trodelvy |
| Genentech USA, INC. | $2,183.69 | 2019-2025 | Itovebi, Phesgo |
| Eli Lilly and Company | $1,000.00 | 2025 | |
| Janssen Biotech, INC. | $100.68 | 2019-2024 | Darzalex, Tecvayli, Talvey |
| Merck Sharp & Dohme LLC | $86.79 | 2019-2024 | Lynparza, Keytruda |
| Daiichi Sankyo INC. | $73.12 | 2024-2025 | Enhertu |
| Jazz Pharmaceuticals INC. | $58.77 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $31.09 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $30.36 | 2019-2020 | |
| Tersera Therapeutics LLC | $26.34 | 2023 | Zoladex |
| Stemline Therapeutics INC. | $24.59 | 2024 | Orserdu |
| Pharmaessentia USA Corporation | $22.26 | 2024 | Besremi |
| Array Biopharma INC | $21.86 | 2024 | Tukysa, Braftovi, Mektovi |
| Astellas Pharma US INC | $21.85 | 2023 | Padcev |
| Incyte Corporation | $19.54 | 2025 | Jakafi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Zelkowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.